Tamer Mahmoud Abdelfattah Mohamed, PhD
Associate Professor / Director of the Center for Cardiac Engineering and Regenerative Therapeutics (CERT)
Positions
- Associate Professor / Director of the Center for Cardiac Engineering and Regenerative Therapeutics (CERT)
-
Division of Cardiothoracic Surgery
ÌÇÐÄÊÓƵ of Medicine
- Associate Professor
-
Medicine
University of Louisville
Louisville, Kentucky, United States
- Scientist II
-
Gene Therapy
Tenaya Therapeutics
San Francisco, California, United States
Addresses
- McNair Campus (MCHP) (Lab)
-
Room: MCHP-A06.182
Houston, TX, 77030
United States
- McNair Campus (MCHP) (Office)
-
Room: MCHP-A06.182
Houston, TX, 77030
United States
Education
- Postdoctoral Training at Gladstone Institute
- 10/2017 - San Francisco, California, United States
- PhD from University of Manchester
- 05/2008 - Manchester, United Kingdom
- MSc from Zagazig University
- 03/2003 - Zagazig
- PharmD from Zagazig University
- 05/1999 - Zagazig, Egypt
Professional Interests
Professional Statement
Tamer M. Mohamed, Ph.D., M.Sc., has broad expertise in molecular cardiology and drug screening in addition to cardiac regeneration and epigenetics. During his research endeavors, he studied novel mechanisms and therapies for cardiac hypertrophy and heart failure.
His research had a major impact on two approaches for endogenous heart repair: direct cardiac reprogramming and inducing cardiomyocyte proliferation. Both approaches were highly successful.
The direct reprogramming approach was the nucleus for an emerging start-up (Tenaya Therapeutics) where he was the first scientist recruited to the company to lead the efforts of direct cardiac reprogramming.
Due to the quick success of Tenaya, which IPO in August 2021 to start clinical trials, the research and development section ended very soon and now the major focus is on scaling up viral manufacturing and filing IND which is away from his interest. Therefore, he decided to go back to academia to initiate new discovery programs for heart failure therapy mainly focusing on understanding the regulation of cardiomyocyte proliferation (Abouleisa et al., Circulation, 2022, and Mohamed et al., Cell, 2018).
Most recently, his laboratory established a novel system for long-term culture of human and pig heart slices and efficiently demonstrated the efficacy of new cardiac regenerative therapies in such pre-clinical models (Ou et al., Circulation Research, 2019). This technology has opened a new avenue of research to explore pathophysiological mechanisms and toxicities in primary pig and human heart tissues.
His research had a major impact on two approaches for endogenous heart repair: direct cardiac reprogramming and inducing cardiomyocyte proliferation. Both approaches were highly successful.
The direct reprogramming approach was the nucleus for an emerging start-up (Tenaya Therapeutics) where he was the first scientist recruited to the company to lead the efforts of direct cardiac reprogramming.
Due to the quick success of Tenaya, which IPO in August 2021 to start clinical trials, the research and development section ended very soon and now the major focus is on scaling up viral manufacturing and filing IND which is away from his interest. Therefore, he decided to go back to academia to initiate new discovery programs for heart failure therapy mainly focusing on understanding the regulation of cardiomyocyte proliferation (Abouleisa et al., Circulation, 2022, and Mohamed et al., Cell, 2018).
Most recently, his laboratory established a novel system for long-term culture of human and pig heart slices and efficiently demonstrated the efficacy of new cardiac regenerative therapies in such pre-clinical models (Ou et al., Circulation Research, 2019). This technology has opened a new avenue of research to explore pathophysiological mechanisms and toxicities in primary pig and human heart tissues.
Selected Publications
-
" ;
Pubmed PMID: . -
" ;
Pubmed PMID: . -
" ;
Pubmed PMID: . -
" ;
Pubmed PMID: .
Funding
-
Transient expression of the cell cycle factors to treat ischemic heart failure
- Grant funding from NIH
-
An Innovative Therapeutic Approach to Treat Cardiomyopathy
- Department of Defence
-
Model evaluation and evaluating the efficacy of compounds in in vitro cultured human heart tissue slices
- Merck
-
Physiologically relevant cardiac tissue culture model for drug testing and disease modeling
- NIH
-
Mechanisms of L-Type Calcium Channel Regulation in Heart Health and Disease
- NIH
-
test the efficacy of an AAV vector on human heart slices
- Tenaya Therapeutics
Intellectual Property
- Methods for inducing cell division of postmitotic cells
- Method Patent (Approved)
- Enhanced direct cardiac reprogramming
- Method Patent (Approved)
- A physiological biomimetic culture system for heart slices
- Method Patent (Pending)
- Biomimetic heart tissue culture system
- Method Patent (Pending)
Languages
Arabic
to edit your profile